直接抗病毒药物联合利巴韦林对老年基因1b型慢性丙型肝炎代偿期肝硬化患者疗效及安全性分析

摘要/Abstract

摘要： 目的评估直接抗病毒药物联合利巴韦林对老年基因1b型慢性丙型肝炎代偿期肝硬化患者的疗效及安全性。方法选取我院2021年4月—2022年4月安康市中医医院收治的老年基因1b型慢性丙型肝炎代偿期肝硬化患者120例,给予直接抗病毒药物联合利巴韦林干预,观察患者丙型肝炎病毒(HCV)RNA转阴率、病毒学应答情况、肝功能指标及不良反应,探讨直接抗病毒药物联合利巴韦林的疗效及安全性。结果 HCV RNA转阴率(66.7%、82.5%、93.3%)随着治疗时间的延长而逐渐升高(P<0.05)。随着治疗结束时间的延长,持续病毒学反应获得率(93.3%、89.2%、86.7%)逐渐降低,但差异无统计学意义(P>0.05)。相较于治疗前的总胆红素(TBil)、丙氨酸氨基转移酶(ALT)、天冬氨酸氨基转移酶(AST)水平[(21.6±3.2)μmol/L、(128.7±14.6)U/L、(83.6±9.3)U/L],治疗后均明显降低[(17.1±2.4)μmol/L、(34.2±5.8)U/L、(26.4±4.7)U/L](P<0.05)。部分患者治疗期间伴有不良反应,头晕乏力者10例,占比为8.3%;血压异常、血糖升高者各5例,占比为4.2%;胃肠道反应者4例,占比为3.3%,上述不良反应经对症治疗后全部恢复正常,患者均可耐受。结论老年基因1b型慢性丙型肝炎代偿期肝硬化患者应用直接抗病毒药物联合利巴韦林治疗具有良好疗效,能够促进HCV RNA转阴,获得持续病毒学反应,并改善肝功能指标水平,临床应用安全性较高。

关键词: 慢性丙型肝炎, 基因1b型, 代偿期肝硬化, 直接抗病毒药物, 利巴韦林

Abstract: Objective To evaluate the efficacy and safety of direct-acting antiviral drugs in combination with ribavirin in elderly patients with compensated liver cirrhosis caused by genotype 1b chronic hepatitis C.Methods From April 2021 to April 2022, a total of 120 elderly patients with compensated cirrhosis caused by genotype 1b chronic hepatitis C were treated with a combination of direct-acting antiviral drug and ribavirin in our hospital. We evaluated the seroconversion rate of hepatitis C virus (HCV) RNA, virology response, liver function indicators, and adverse reactions to assess the efficacy and safety of this treatment regimen.Results The seroconversion rate of HCV RNA (66.7%, 82.5%, 93.3%) showed a progressive increase with the duration of treatment time (P<0.05). As the treatment period extended, the sustained virological response rate (93.3%, 89.2%, 86.7%) gradually decreased, but the difference was not statistically significant (P>0.05). Compared to the pre-treatment levels of total bilirubin (TBil), alanine transaminase (ALT), and aspartate transaminase (AST) [(21.6 ± 3.2) μmol/L, (128.7 ± 14.6) U/L, (83.6 ± 9.3) U/L], the levels were significantly decreased after treatment [(17.1 ± 2.4) μmol/L, (34.2 ± 5.8) U/L, (26.4 ± 4.7) U/L] (P<0.05). During the course of treatment, some patients experienced adverse reactions, including 10 cases of dizziness and fatigue ,(8.3%), 5 cases of abnormal blood pressure (4.2%), 5 cases of elevated blood sugar (4.2%), and 4 cases of gastrointestinal reactions (3.3%). All of these adverse reactions resolved after symptomatic treatment, and the patients were able to tolerate them.Conclusion The use of direct antiviral drugs combined with ribavirin in the treatment of elderly patients with compensated liver cirrhosis caused by genotype 1b chronic hepatitis C has demonstrated good efficacy. It has been shown to promote the seroconversion of HCV RNA, achieve sustained virological response, and improve the level of liver function indicators. Furthermore, this treatment regimen has a high level of clinical safety.

Key words: Chronic hepatitis C, Genotype 1b, Compensatory cirrhosis, Direct antiviral drugs, Ribavirin

苏静波, 曹广华. 直接抗病毒药物联合利巴韦林对老年基因1b型慢性丙型肝炎代偿期肝硬化患者疗效及安全性分析[J]. 肝脏, 2023, 28(12): 1459-1461.

SU Jing-bo, CAO Guang-hua. Analysis of the efficacy and safety of direct antiviral drugs combined with ribavirin in elderly patients with compensated liver cirrhosis caused by genotype 1b chronic hepatitis C[J]. Chinese Hepatolgy, 2023, 28(12): 1459-1461.

参考文献

[1] Lupberger J, Croonenborghs T, Suarez AAR, et al. Combined analysis of metabolomes, proteomes, and transcriptomes of hepatitis C virus-infected cells and liver to identify pathways associated with disease development[J]. Gastroenterology,2019,157(2):537-551.
[2] Borgia SM, Hedskog C, Parhy B, et al. Identification of a novel hepatitis C virus genotype from Punjab, India: expanding classification of hepatitis C virus into 8 genotypes[J]. J Infect Dis,2018,218(11):1722-1729.
[3] 任姗, 金怡, 柳雅立, 等. 聚乙二醇干扰素联合利巴韦林治疗对基因1b型慢性丙型肝炎患者预存耐药相关替代的差异性分析[J]. 北京医学,2020,42(6):479-484,488.
[4] 贺秋凤, 胡蓉, 曾义岚, 等. 索磷布韦/维帕他韦联合或不联合利巴韦林治疗基因3型慢性丙型肝炎病毒感染者的疗效及安全性:一项真实世界研究[J]. 中国肝脏病杂志(电子版)2022,14(1):6-13.
[5] Enomoto M, Ikura Y, Tamori A, et al. Short-term histological evaluations after achieving a sustained virologic response to direct-acting antiviral treatment for chronic hepatitis C[J]. United European Gastroenterol J,2018,6(9):1391-1400.
[6] 中华医学会肝病学分会, 中华医学会感染病学分会. 丙型肝炎防治指南(2019年版)[J]. 实用肝脏病杂志,2020,23(1):后插33-后插52.
[7] Wehmeyer MH, Ingiliz P, Christensen S, et al. Real-world effectiveness of sofosbuvir-based treatment regimens for chronic hepatitis C genotype 3 infection: Results from the multicenter German hepatitis C cohort (GECCO-03)[J]. J Med Virol,2018,90(2):304-312.
[8] Singal AG, Lim JK, Kanwal F. AGA clinical practice update on interaction between oral direct-acting antivirals for chronic hepatitis C infection and hepatocellular carcinoma: expert review[J]. Gastroenterology,2019,156(8):2149-2157.
[9] Ogawa E, Furusyo N, Nakamuta M, et al. Glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C genotype 1 or 2 infection: results from a multicenter, real-world cohort study[J]. Hepatol Res,2019,49(6):617-626.
[10] Mohamed AA, Omar AAA, El-Awady RR, et al. MiR-155 and MiR-665 role as potential non-invasive biomarkers for hepatocellular carcinoma in Egyptian patients with chronic hepatitis C virus infection[J]. J Transl Intern Med,2020,8(1):32-40.
[11] Damiani G, Franchi C, Pigatto P, et al. Outcomes assessment of hepatitis C virus-positive psoriatic patients treated using pegylated interferon in combination with ribavirin compared to new Direct-Acting Antiviral agents[J]. World J Hepatol,2018,10(2):329.
[12] Goñi Esarte S, Juanbeltz R, Martinez-Baz I, et al. Long-term changes on health-related quality of life in patients with chronic hepatitis C after viral clearance with direct-acting antiviral agents[J]. Rev Esp Enferm Dig,2019,111(6):445-452.
[13] Tamori A, Abiru S, Enomoto H, et al. Low incidence of hepatitis B virus reactivation and subsequent hepatitis in patients with chronic hepatitis C receiving direct-acting antiviral therapy[J]. J Viral Hepatitis,2018,25(5):608-611.
[14] 揭育胜, 袁静, 张晓红, 等. 奥比帕利联合达塞布韦用于中国基因1b型丙型肝炎病毒慢性感染的真实世界研究[J]. 中华肝脏病杂志,2019,27(2):123-127.
[15] Singh S, Facciorusso A, Loomba R, et al. Magnitude and kinetics of decrease in liver stiffness after antiviral therapy in patients with chronic hepatitis C: a systematic review and meta-analysis[J]. Clin Gastroenterol H,2018,16(1):27-38.
[16] 侯艺辉, 刘腾飞, 赵晓青, 等. 不同直接抗病毒药物方案对基因1b型慢性丙型肝炎及代偿期丙型肝炎肝硬化临床结局的影响[J]. 临床肝胆病杂志,2020,36(1):84-87.
[17] Ji F, Yeo YH, Wei MT, et al. Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: a systematic review and meta-analysis[J]. J Hepatol,2019,71(3):473-485.
[18] Mettke F, Schlevogt B, Deterding K, et al. Interferon-free therapy of chronic hepatitis C with direct-acting antivirals does not change the short-term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis[J]. Aliment Pharm Ther,2018,47(4):516-525.